BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Trading Down 5.8% – Should You Sell?

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) traded down 5.8% on Wednesday . The stock traded as low as $8.83 and last traded at $8.91. 62,797 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 315,392 shares. The stock had previously closed at $9.46.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. HC Wainwright lifted their price objective on BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the company a “buy” rating in a report on Friday, March 6th. Weiss Ratings initiated coverage on BridgeBio Oncology Therapeutics in a research note on Wednesday, January 14th. They issued a “sell (d+)” rating on the stock. Raymond James Financial upgraded BridgeBio Oncology Therapeutics to a “moderate buy” rating in a research note on Friday, January 9th. Finally, Stifel Nicolaus initiated coverage on BridgeBio Oncology Therapeutics in a research note on Tuesday, February 10th. They issued a “buy” rating and a $23.00 price target on the stock. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, BridgeBio Oncology Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $26.00.

BridgeBio Oncology Therapeutics Stock Performance

The stock has a market cap of $714.67 million, a price-to-earnings ratio of -5.90 and a beta of 0.51. The stock has a 50-day simple moving average of $9.60.

Institutional Investors Weigh In On BridgeBio Oncology Therapeutics

A number of institutional investors have recently made changes to their positions in BBOT. Geode Capital Management LLC grew its position in shares of BridgeBio Oncology Therapeutics by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 561,987 shares of the company’s stock valued at $7,039,000 after buying an additional 20,385 shares during the last quarter. Goldman Sachs Group Inc. bought a new stake in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at about $1,185,000. BIT Capital GmbH bought a new stake in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at about $313,000. CIBC Private Wealth Group LLC bought a new stake in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at about $63,000. Finally, Renaissance Technologies LLC acquired a new position in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at about $930,000. Institutional investors own 54.89% of the company’s stock.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.